Samantha Tam1, Christopher M K L Yao1, Moran Amit1, Mona Gajera1, Xiaoning Luo1, Rachel Treistman1, Anshu Khanna1, Mohamed Aashiq1, Priyadharsini Nagarajan2, Diana Bell2, Adel El-Naggar2, Michael Migden3, Michael Wong4, Bonnie Glisson5, Renata Ferrarotto5, Bita Esmaeli6, David Rosenthal7, Guojun Li1, Randal S Weber1, Jeffrey N Myers1, Neil D Gross1. 1. Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston. 2. Division of Pathology and Laboratory Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston. 3. Division of Internal Medicine, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston. 4. Division of Cancer Medicine, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston. 5. Division of Cancer Medicine, Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston. 6. Division of Surgery, Department of Plastic Surgery, Ophthalmic Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
Abstract
Importance: Patients with immunosuppression have a higher incidence of cutaneous squamous cell carcinoma (cSCC) and often present with more aggressive, multifocal disease. Objectives: To determine the risks for mortality in patients with cSCC and immunosuppression compared with nonimmunosuppression and to compare the difference in mortality risk based on the cause of immunocompromise. Design, Setting, and Participants: This retrospective cohort study of patients with cSCC of the head and neck recruited participants from a tertiary cancer care center. Patients who underwent no treatment, wide local excision, or biopsy of the lesions were eligible for inclusion from January 1, 1995, to September 30, 2015. Data were analyzed from March 21, 2018, to April 4, 2019. Exposures: Immunocompromise, defined as having solid organ transplant, stem cell transplant, hematopoetic malignant disease, autoimmune disease requiring treatment with immunosuppressive therapy, type 1 or 2 diabetes treated with insulin, HIV or AIDS, or other hematoproliferative disorder. Main Outcomes and Measures: Patients were divided into 2 groups according to their immune status (immunosuppression vs no immunosuppression). The primary outcome measure was disease-specific survival. A Cox proportional hazards regression model was used to determine the association of immune status with disease outcome. Results: A total of 796 patients (680 men [85.4%]; median age, 69 [range, 27-98] years), including 147 with and 649 without immunosuppression (IS and non-IS groups, respectively), constituted the final cohort. In the IS group, 77 (52.4%) had diabetes, 39 (26.5%) had lymphoma or leukemia, 25 (17.0%) had an organ or stem cell transplant, and 3 (2.0%) had HIV. Five-year disease-specific survival was 68.2% in the IS group compared with 84.1% in the non-IS group (difference, 15.9%; 95% CI, 3.5%-27.4%). Immunosuppression was independently associated with worse disease-specific survival (hazard ratio, 2.32; 95% CI, 1.53-3.50). Conclusions and Relevance: This study's findings suggest that immunosuppression is independently associated with a worse outcome in cSCC, with a 2.32 times increased risk of disease-specific death after adjusting for age, history of skin cancer, recurrent or persistent disease status, disease stage, and treatment.
Importance: Patients with immunosuppression have a higher incidence of cutaneous squamous cell carcinoma (cSCC) and often present with more aggressive, multifocal disease. Objectives: To determine the risks for mortality in patients with cSCC and immunosuppression compared with nonimmunosuppression and to compare the difference in mortality risk based on the cause of immunocompromise. Design, Setting, and Participants: This retrospective cohort study of patients with cSCC of the head and neck recruited participants from a tertiary cancer care center. Patients who underwent no treatment, wide local excision, or biopsy of the lesions were eligible for inclusion from January 1, 1995, to September 30, 2015. Data were analyzed from March 21, 2018, to April 4, 2019. Exposures: Immunocompromise, defined as having solid organ transplant, stem cell transplant, hematopoetic malignant disease, autoimmune disease requiring treatment with immunosuppressive therapy, type 1 or 2 diabetes treated with insulin, HIV or AIDS, or other hematoproliferative disorder. Main Outcomes and Measures: Patients were divided into 2 groups according to their immune status (immunosuppression vs no immunosuppression). The primary outcome measure was disease-specific survival. A Cox proportional hazards regression model was used to determine the association of immune status with disease outcome. Results: A total of 796 patients (680 men [85.4%]; median age, 69 [range, 27-98] years), including 147 with and 649 without immunosuppression (IS and non-IS groups, respectively), constituted the final cohort. In the IS group, 77 (52.4%) had diabetes, 39 (26.5%) had lymphoma or leukemia, 25 (17.0%) had an organ or stem cell transplant, and 3 (2.0%) had HIV. Five-year disease-specific survival was 68.2% in the IS group compared with 84.1% in the non-IS group (difference, 15.9%; 95% CI, 3.5%-27.4%). Immunosuppression was independently associated with worse disease-specific survival (hazard ratio, 2.32; 95% CI, 1.53-3.50). Conclusions and Relevance: This study's findings suggest that immunosuppression is independently associated with a worse outcome in cSCC, with a 2.32 times increased risk of disease-specific death after adjusting for age, history of skin cancer, recurrent or persistent disease status, disease stage, and treatment.
Authors: Bindu V Manyam; Adam A Garsa; Re-I Chin; Chandana A Reddy; Brian Gastman; Wade Thorstad; Sue S Yom; Brian Nussenbaum; Steven J Wang; Allison T Vidimos; Shlomo A Koyfman Journal: Cancer Date: 2017-02-07 Impact factor: 6.860
Authors: Ellen N Pritchett; Alden Doyle; Christine M Shaver; Brett Miller; Mark Abdelmalek; Carrie Ann Cusack; Gregory E Malat; Christina Lee Chung Journal: JAMA Dermatol Date: 2016-12-01 Impact factor: 10.282
Authors: Shlomo A Koyfman; Jay S Cooper; Jonathan J Beitler; Paul M Busse; Christopher U Jones; Mark W McDonald; Harry Quon; John A Ridge; Nabil F Saba; Joseph K Salama; Farzan Siddiqui; Richard V Smith; Francis Worden; Min Yao; Sue S Yom Journal: Head Neck Date: 2016-02 Impact factor: 3.147
Authors: Arielle N B Kauvar; Christopher J Arpey; George Hruza; Suzanne M Olbricht; Richard Bennett; Bassel H Mahmoud Journal: Dermatol Surg Date: 2015-11 Impact factor: 3.398
Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: Gerald S Falchook; Rom Leidner; Elizabeth Stankevich; Brian Piening; Carlo Bifulco; Israel Lowy; Matthew G Fury Journal: J Immunother Cancer Date: 2016-11-15 Impact factor: 13.751
Authors: Catherine A Harwood; Charlotte M Proby; Jane M McGregor; Michael T Sheaff; Irene M Leigh; Rino Cerio Journal: J Am Acad Dermatol Date: 2006-02 Impact factor: 11.527
Authors: Flora Yan; Brittny N Tillman; Rajiv I Nijhawan; Divya Srivastava; David J Sher; Vladimir Avkshtol; Jade Homsi; Justin A Bishop; Erin M Wynings; Rebecca Lee; Larry L Myers; Andrew T Day Journal: Ann Surg Oncol Date: 2021-06-30 Impact factor: 5.344
Authors: Renata Ferrarotto; Moran Amit; Priyadharsini Nagarajan; M Laura Rubin; Ying Yuan; Diana Bell; Adel K El-Naggar; Jason M Johnson; William H Morrison; David I Rosenthal; Bonnie S Glisson; Faye M Johnson; Charles Lu; Frank E Mott; Bita Esmaeli; Eduardo M Diaz; Paul W Gidley; Ryan P Goepfert; Carol M Lewis; Randal S Weber; Jennifer A Wargo; Sreyashi Basu; Fei Duan; Shalini S Yadav; Padmanee Sharma; James P Allison; Jeffrey N Myers; Neil D Gross Journal: Clin Cancer Res Date: 2021-06-29 Impact factor: 12.531
Authors: Ignazio Stanganelli; Francesco Spagnolo; Giuseppe Argenziano; Paolo A Ascierto; Franco Bassetto; Paolo Bossi; Vittorio Donato; Daniela Massi; Cesare Massone; Roberto Patuzzo; Giovanni Pellacani; Pietro Quaglino; Paola Queirolo; Iris Zalaudek; Giuseppe Palmieri Journal: Cancers (Basel) Date: 2022-01-13 Impact factor: 6.639